特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品受託製造開発機関(CDMO)アウトソーシングの世界市場:2019年~2023年

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market by Product and Geography - Global Forecast and Analysis 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 655618
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.98円で換算しております。
医薬品受託製造開発機関(CDMO)アウトソーシングの世界市場:2019年~2023年 Contract Development and Manufacturing Organization (CDMO) Outsourcing Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日: 2019年09月11日 ページ情報: 英文 136 Pages
概要

世界のCDMOアウトソーシング市場は、成長する医薬品業界、ワンストップショップCDMOの需要の増加、運用および資本費用の削減におけるCDMOのサポートなどが要因となり、予測期間中に約8%のCAGRで拡大する見込みです。ただし、知的所有(IP)権の侵害の脅威、複数の生産ラインが原因でCDMOが直面するシリアル化の問題、規制の順守などの要因で、予測期間中のCDMOアウトソーシング業界の成長が妨げられる可能性があります。

当レポートでは、世界の医薬品受託製造開発機関(CDMO)アウトソーシング市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 比較:製品市場規模および予測(2018年~2023年)
  • 小分子
  • 生物製剤
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米
  • 欧州
  • アジア太平洋地域
  • 南米
  • 中東・アフリカ地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • CDMOによるアナリティクスの活用の拡大
  • 細胞および遺伝子治療のためのCDMOの需要の増加
  • 市場統合の増加

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Aenova Holding GmbH
  • Almac Group Ltd.
  • Catalent Inc.
  • FAMAR Health Care Services
  • FAREVA SA
  • Lonza Group Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • The Lubrizol Corp.
  • Thermo Fisher Scientific Inc.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR32014

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market: About this market

Contract development and manufacturing organizations (CDMO) serve companies in the pharmaceutical industry on a contract basis. Technavio's CDMO outsourcing market analysis considers sales from small molecules and biologics products. Our analysis also considers the sales of CDMO outsourcing products in APAC, Europe, North America, South America, and MEA. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing focus of vendors on expanding their presence will play a significant role in the small molecules segment to maintain its market position. Also, our global CDMO market report looks at factors such as the growing pharmaceutical industry, increasing demand for one-stop-shop CDMOs, and support of CDMOs in reducing the operational and capital expenses. However, the threat of infringement of intellectual property (IP) rights, serialization issue faced by CDMOs due to multiple production lines and need to comply with regulations may hamper the growth of the CDMO outsourcing industry over the forecast period.

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market: Overview

Increasing demand for one-stop-shop CDMOs

One-stop-shop CDMOs have high expertise in gaining a competitive edge in the market. They consider various parameters including country-specific requirements, cost efficiency, patient friendliness, and product safety to offer customization of packaging. This enables pharma and biotech firms to safely launch their products in the market. CDMOs not only preserves scarce APIs but also monitors the entire value chain of a product. Such benefits of CDMOs will lead to the expansion of the global contract development and manufacturing organization (CDMO) outsourcing market at a CAGR of almost 8% during the forecast period.

Increasing market consolidation

M&As among CDMOs helps in the expansion of the customer base in new regions and improve the market reach. This inorganic strategy also aids in acquiring technological expertise and develop new innovative products to achieve differentiation from competitors. These developments are increasing consolidation in the market, which is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global contract development and manufacturing organization (CDMO) outsourcing market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global CDMO outsourcing market is highly fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading CDMO outsourcing manufacturers, that include Aenova Holding GmbH, Almac Group Ltd., Catalent Inc., FAMAR Health Care Services, FAREVA SA, Lonza Group Ltd., Recipharm AB, Siegfried Holding AG, The Lubrizol Corp., and Thermo Fisher Scientific Inc.

Also, the CDMO outsourcing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • South America - Market size and forecast 2018-2023
  • MEA - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Growing use of analytics by CDMOs
  • Growing demand for CDMOs for cell and gene therapies
  • Increasing market consolidation

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aenova Holding GmbH
  • Almac Group Ltd.
  • Catalent Inc.
  • FAMAR Health Care Services
  • FAREVA SA
  • Lonza Group Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • The Lubrizol Corp.
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

  • Exhibit 01: Vendors: Key product offerings
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: APAC - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: South America - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 35: South America - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: MEA - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 37: MEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Aenova Holding GmbH - Vendor overview
  • Exhibit 47: Aenova Holding GmbH - Service segments
  • Exhibit 48: Aenova Holding GmbH - Organizational developments
  • Exhibit 49: Aenova Holding GmbH - Key offerings
  • Exhibit 50: Almac Group Ltd. - Vendor overview
  • Exhibit 51: Almac Group Ltd. - Product segments
  • Exhibit 52: Almac Group Ltd. - Organizational developments
  • Exhibit 53: Almac Group Ltd. - Key offerings
  • Exhibit 54: Catalent Inc. - Vendor overview
  • Exhibit 55: Catalent Inc. - Business segments
  • Exhibit 56: Catalent Inc. - Organizational developments
  • Exhibit 57: Catalent Inc. - Geographic focus
  • Exhibit 58: Catalent Inc. - Segment focus
  • Exhibit 59: Catalent Inc. - Key offerings
  • Exhibit 60: FAMAR Health Care Services - Vendor overview
  • Exhibit 61: FAMAR Health Care Services - Service segments
  • Exhibit 62: FAMAR Health Care Services - Organizational developments
  • Exhibit 63: FAMAR Health Care Services - Key offerings
  • Exhibit 64: FAREVA SA - Vendor overview
  • Exhibit 65: FAREVA SA - Business segments
  • Exhibit 66: FAREVA SA - Organizational developments
  • Exhibit 67: FAREVA SA - Key offerings
  • Exhibit 68: Lonza Group Ltd. - Vendor overview
  • Exhibit 69: Lonza Group Ltd. - Business segments
  • Exhibit 70: Lonza Group Ltd. - Organizational developments
  • Exhibit 71: Lonza Group Ltd. - Geographic focus
  • Exhibit 72: Lonza Group Ltd. - Segment focus
  • Exhibit 73: Lonza Group Ltd. - Key offerings
  • Exhibit 74: Recipharm AB - Vendor overview
  • Exhibit 75: Recipharm AB - Business segments
  • Exhibit 76: Recipharm AB - Organizational developments
  • Exhibit 77: Recipharm AB - Geographic focus
  • Exhibit 78: Recipharm AB - Segment focus
  • Exhibit 79: Recipharm AB - Key offerings
  • Exhibit 80: Siegfried Holding AG - Vendor overview
  • Exhibit 81: Siegfried Holding AG - Product segments
  • Exhibit 82: Siegfried Holding AG - Organizational developments
  • Exhibit 83: Siegfried Holding AG - Segment focus
  • Exhibit 84: Siegfried Holding AG - Key offerings
  • Exhibit 85: The Lubrizol Corp. - Vendor overview
  • Exhibit 86: The Lubrizol Corp. - Business segments
  • Exhibit 87: The Lubrizol Corp. - Organizational developments
  • Exhibit 88: The Lubrizol Corp. - Key offerings
  • Exhibit 89: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 90: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 91: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 92: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 93: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 94: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 95: Validation techniques employed for market sizing
  • Exhibit 96: Definition of market positioning of vendors